Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
3.01B | 3.59B | 3.62B | 3.55B | 2.95B | 2.33B | Gross Profit |
1.37B | 1.71B | 1.64B | 1.55B | 1.38B | 1.05B | EBIT |
693.10M | 498.00M | -1.55B | 617.00M | 698.90M | 453.80M | EBITDA |
808.90M | 870.00M | -1.18B | 888.00M | 795.00M | 551.30M | Net Income Common Stockholders |
555.20M | 190.00M | -1.84B | 333.00M | 551.00M | 350.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
714.00M | 714.00M | 875.00M | 910.00M | 1.04B | 836.00M | Total Assets |
8.59B | 8.59B | 9.12B | 11.49B | 4.54B | 3.90B | Total Debt |
261.00M | 261.00M | 5.02B | 5.17B | 1.03B | 1.03B | Net Debt |
-453.00M | -453.00M | 4.15B | 4.26B | 61.20M | 419.10M | Total Liabilities |
6.27B | 6.27B | 6.65B | 7.01B | 1.65B | 1.54B | Stockholders Equity |
2.32B | 2.32B | 2.47B | 4.48B | 2.89B | 2.36B |
Cash Flow | Free Cash Flow | ||||
366.50M | 410.00M | 232.00M | 365.00M | 552.80M | 428.30M | Operating Cash Flow |
493.40M | 528.00M | 319.00M | 529.00M | 639.50M | 513.20M | Investing Cash Flow |
-105.70M | -117.00M | -84.00M | -4.55B | -204.60M | -202.40M | Financing Cash Flow |
-55.00M | -549.00M | -259.00M | 3.97B | -65.00M | -121.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $98.12B | 23.23 | 48.75% | 1.13% | 13.21% | 27.25% | |
77 Outperform | $271.75B | 34.01 | 40.98% | 0.82% | 2.53% | -3.33% | |
76 Outperform | $124.20B | 20.00 | 34.06% | 1.05% | 4.45% | -10.01% | |
70 Outperform | $17.34B | 32.29 | 14.62% | 0.45% | 5.52% | 16.59% | |
69 Neutral | $92.89B | 29.40 | 89.51% | 0.91% | 12.19% | 20.80% | |
65 Neutral | $5.76B | 30.43 | 8.18% | 1.03% | -0.99% | ― | |
59 Neutral | $22.39B | 11.53 | -18.05% | 2.31% | 5.00% | -25.89% |
On January 24, 2025, MKS Instruments announced the successful repricing of its $2.5 billion USD and €596 million EUR secured tranche B term loans maturing in 2029, resulting in reduced interest rates and a voluntary prepayment of $100 million, lowering the USD tranche B principal to $2.5 billion. This repricing is expected to generate approximately $15 million in annualized cash interest savings, indicating the company’s ongoing efforts to deleverage its balance sheet and enhance free cash flow. The move underscores MKS Instruments’ strategic initiatives to cut costs and optimize financial operations, enhancing its market positioning and stakeholder value.